Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - Intervention Development
Public ClinicalTrials.gov record NCT04077138. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Transgender Youth and PrEP: PK, Safety, Uptake & Adherence
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To address the critical scientific gaps in PrEP safety for transgender youth and to plan for appropriate implementation of PrEP in transgender youth communities, the study will be conducted in 3 integrated phases. In Phase 1, a pharmacokinetic (PK) study exploring the interactions of cs-HT for both TW and TM youth on TDF/FTC will be conducted. Simultaneously, in Phase 2, ethnographic data via focus groups (FGs) and in-depth interviews (IDIs) to inform the development of a tailored intervention to improve uptake and adherence to PrEP for transgender youth will be collected. In Phase 3, a small demonstration trial of PrEP use in transgender youth, utilizing the ethnographically developed intervention to improve uptake and adherence, while also monitoring renal and bone safety outcomes will be implemented. The project has the following important specific aims: Aim 1: To evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among 24 TW taking estradiol and 24 TM taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily adherence and maximize drug exposure. Aim 2: To develop a culturally, developmentally, and gender-affirmative intervention to increase uptake of and adherence to PrEP among TW and TM youth that is grounded in theory (Information-Motivation-Behavioral Skills Model of Behavior Change, Gender Affirmation, Empowerment Theory) and incorporates the PK data from Aim 1. Investigators will conduct FGs with young TW (N=20-30) and TM (N=20-30) and conduct IDIs with participants from the PK study (Total N=10-14). Investigators will solicit continuous input and feedback from TW and TM on the project's Youth Advisory Board. Aim 3: To conduct a small randomized controlled trial within a PrEP demonstration project comparing the newly developed intervention with standard of care (SOC) in TW (N=50) and TM (N=50) ages 15-24 years.
Study identification
- NCT ID
- NCT04077138
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 15 Years to 24 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2018
- Primary completion
- Nov 29, 2023
- Completion
- Nov 29, 2023
- Last update posted
- Mar 31, 2024
2019 – 2023
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado, Denver | Denver | Colorado | 80045 | — |
| John H. Stroger, Jr. Hospital of Cook County | Chicago | Illinois | 60612 | — |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated HIV/AIDS trials
Other public records listing HIV/AIDS. Sorted by last update posted; newest first. Not a recommendation.
- NCT03729778: Impact of HIV-1 and Aging on Mucosal Vaccine Responses Active, not recruiting
- NCT06462807: Enhancing the Organizational Social Context to Improve Viral Suppression and Retention in HIV Care Recruiting
- NCT05877729: Intervention for Virologic Suppression in Youth Active, not recruiting
- NCT06741618: MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM Recruiting
- NCT04019197: Effects of Semaglutide in HIV-Associated Lipohypertrophy Active, not recruiting
- NCT04378439: Appalachian Partnership to Reduce Disparities (Aim 2) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04077138, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04077138 live on ClinicalTrials.gov.